Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of atazanavir in preparation of medicine for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

A technology for acute respiratory distress and acute lung injury, which is applied in the application field of atazanavir in the preparation of medicines for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis. And other issues

Inactive Publication Date: 2014-08-20
BINZHOU MEDICAL COLLEGE
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Clinically, atazanavir sulfate capsules are used in combination with other antiretroviral drugs to treat HIV-1 infection, but the pharmacological effects of atazanavir in the prevention or treatment of ALI / ARDS and pulmonary fibrosis have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of atazanavir in preparation of medicine for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Application of atazanavir in preparation of medicine for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis
  • Application of atazanavir in preparation of medicine for preventing or treating acute lung injury/acute respiratory distress syndrome and pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Preparation of Atazanavir Sulfate Freeze-Dried Powder for Injection

[0013] Take 100.0g of atazanavir sulfate, add 2000ml of water for injection to dissolve it, add 8g of mannitol, stir to dissolve, and ultra-filter to obtain a pyrogen-free clear liquid, pour it into a 10ml vial, 2ml / bottle, press the freeze-dried powder Freeze-dried by needle process to make freeze-dried powder injections each containing 100.0 mg of atazanavir sulfate.

Embodiment 2

[0014] Example 2 Preparation of atazanavir sulfate capsules

[0015] Weigh 200.0g of atazanavir sulfate and 100.0g of sodium carboxymethyl starch, mix well and pass through a 100-mesh sieve, add an appropriate amount of 3% PVP K30 Appropriate amount of water solution to make soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, sieve with 18-mesh sieve for granulation, add 2.0g of magnesium stearate, mix well and pack into capsules, adjust the weight of the capsules to about 300mg, and the product is ready.

experiment example 2

[0028] Experimental example 2 Effect of atazanavir sulfate on acute lung injury / acute respiratory distress syndrome (ALI / ARDS) model rats caused by cecal ligation and perforation

[0029] 2.1 Drugs and reagents

[0030] Atazanavir sulfate (purity 99.5%, purchased from Dalian Meilun Biotechnology Co., Ltd.)

[0031] Limulus reagent kit (Fuzhou Xinbei Biochemical Industry Co., Ltd., Fujian Province, batch number: 080430)

[0032] Anti-Aquaporin5 antibody (abcam company, ab104751)

[0033] RAGE primary antibody was purchased from Sigma.

[0034] Experimental animals: SPF grade Sprague Dawley rats, male, weighing 150g-200g, provided by the Experimental Animal Center of Shandong Luye Pharmaceutical Co., Ltd., the animal qualification certificate number is: SYXK (Lu) 20030020.

[0035] 2.2 Experimental methods and results

[0036] 2.2.1 Preparation of rats with cecal ligation and puncture (CLP)

[0037] On the day of the operation, the rats were fasted in the morning, placed in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides novel application of atazanavir medicines, and in particular relates to application of atazanavir in inhibiting generation and development of acute lung injury / acute respiratory distress syndrome (ALI / ARDS) and pulmonary fibrosis by inhibiting apoptosis of I type alveolar epithelial cells and promoting expression of receptor for advanced glycation endproducts (RAGE) of I type alveolar epithelial cells, so as to prevent or treat ALI / ARDS and pulmonary fibrosis. According to the application, the injected dose of atazanavir ranges from 100 to 2000mg, preferably 100 to 1000mg; the oral dose of atazanavir ranges from 200 to 6000mg, preferably 200 to 3000mg.

Description

technical field [0001] The present invention relates to that atazanavir suppresses the occurrence and development of acute lung injury / acute respiratory distress syndrome (ALI / ARDS) and pulmonary fibrosis so as to prevent or treat ALI / ARDS and pulmonary fibrosis; Type I alveolar epithelial cell apoptosis, promote the expression of receptor for advanced glycation endproducts (RAGE) in type I alveolar epithelial cells, so as to prevent or treat ALI / ARDS and pulmonary fibrosis. Background technique [0002] Acute lung injury / acute respiratory distress syndrome (ALI / ARDS) is a common critical illness with a high mortality rate, which seriously threatens the life of critically ill patients and affects their quality of life. ALI / ARDS is acute hypoxic respiratory function caused by diffuse pulmonary interstitial and alveolar edema caused by damage to pulmonary capillary endothelial cells and alveolar epithelial cells during non-cardiogenic diseases such as severe infection, shock, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4418A61P11/00
Inventor 蒋王林纪云霞吕长俊
Owner BINZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com